FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of diagnostics and lab services industry veteran John P. “Jack” Kenny to its Board of Directors. Mr. Kenny is filling the seat vacated by Alison Hannah, MD, who is rotating off the Board after more than ten years of dedicated service. Mr. Kenny brings to the NeoGenomics Board over three decades of diverse executive,

Biotech executives and shareholders can breathe easier heading into the new year for the first time in nearly half a decade. The industry’s leaders will arrive at January’s JP Morgan Healthcare Conference riding a surge in M&A activity and the XBI in recovery from a years-long slide. While that exchange-traded fund remains below its pandemic-fueled peak in 2021, it’s above $120 and is up more than 80% from April. That warm glow had been missing since the pandemic sugar high faded and set off a r

New Delhi: Statins , which help treat high cholesterol, may significantly reduce risk of death and major cardiovascular events in adults with type 2 diabetes , including among those considered at low cardiovascular risk , according to a study. The findings published in the journal Annals of Internal Medicine challenge a long-standing uncertainty about whether patients at the lowest risk benefit from preventive statin therapy, and suggest that the drugs may have a broader protective value than pr

Las Vegas-based New Horizon Medical Solutions announced it has acquired Applied Tissue Technologies' transparent negative-pressure wound therapy device and micrografting kit, expanding its portfolio of wound care offerings. New Horizon offers biologics and advanced wound care tools, including skin substitutes developed using amniotic membrane technology. The company also offers workflow and staff training tools, as well as technology integration services, aimed at reducing administrative burden,

Insilico Medicine, one of the original AI-driven drug discoverers, has stuck the landing after four years of trying to go public. The 11-year-old drug developer on Tuesday raised gross proceeds of approximately $293 million via its listing on the Hong Kong Stock Exchange. Insilico’s share price escalated 24% in its first trading session, ending the debut day with a market capitalization of about $2.15 billion (16.71 billion Hong Kong dollars). The biotech’s float was one of the largest Hong Kong

Verastem Oncology is ending an early-stage trial of its MEK inhibitor Avmapki in lung cancer and pivoting to another program that it says could have a greater impact on patients. The biotech said Monday it will discontinue the Phase 1/2 RAMP 203 study testing Avmapki, which has the generic name avutometinib, following a look at some interim data. The trial is assessing a doublet regimen of Avmapki with Amgen’s Lumakras and a triplet with Lumakras and Verastem’s FAK inhibitor Fakzynja (defactinib

NEW YORK, Dec. 30, 2025 /PRNewswire/ -- ALS United Greater New York increased its financial investment in ALS research throughout 2025, accelerating new approaches in ALS treatment, prevention, and understanding. These efforts include an initiative to pool dollars with 11 other ALS United member organizations to fund a robust portfolio of research innovation grants. The commitment and radical collaboration underscores ALS United's collective work to drive global research while strengthening expe

— NDA supported by positive Phase II registration study data in Chinese patients; follows Breakthrough Therapy Designation granted in 2023 — — Savolitinib has the potential to become the first selective MET inhibitor in China for MET-amplified gastric cancer — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 30, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application (“NDA”) for savolitinib for the treatm

HARTFORD, Conn., Dec. 30, 2025 /PRNewswire/ -- ALS United Connecticut increased its financial investment in ALS research throughout 2025, accelerating new approaches in ALS treatment, prevention, and understanding. These efforts include an initiative to pool dollars with 11 other ALS United member organizations to fund a robust portfolio of research innovation grants. The commitment and radical collaboration underscores ALS United's collective work to drive global research while strengthening ex

HONG KONG, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, becoming the first AI-driven biotech company to go public in Main Board under Chapter 8.05 listing rules of the HKEX. This initial public offering (IPO) raised a total of HKD 2.277 billion, achieving the largest biotech IPO in Hong Kong this year, as in the siz